Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-01-31
2011-12-27
Haddad, Maher (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S143100
Reexamination Certificate
active
08084028
ABSTRACT:
Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 5391481 (1995-02-01), Chess et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5788966 (1998-08-01), Chess et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5798230 (1998-08-01), Bornkamm et al.
patent: 5827690 (1998-10-01), Meade et al.
patent: 5855888 (1999-01-01), Nishida et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 6001961 (1999-12-01), Jonczyk et al.
patent: 6016159 (2000-01-01), Faris
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6127524 (2000-10-01), Casipit et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6162963 (2000-12-01), Kucherlapati et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6291650 (2001-09-01), Winter et al.
patent: 6300064 (2001-10-01), Knappik et al.
patent: 6303313 (2001-10-01), Wigler et al.
patent: 6307026 (2001-10-01), King et al.
patent: 6326403 (2001-12-01), Hölzemann et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 6652856 (2003-11-01), Gotwals et al.
patent: 6955810 (2005-10-01), Gotwals et al.
patent: 7462353 (2008-12-01), Gotwals et al.
patent: 0 239 400 (1987-09-01), None
patent: 0 843 961 (1998-05-01), None
patent: 08-131185 (1996-05-01), None
patent: 08131185 (1996-05-01), None
patent: WO 90/07861 (1990-07-01), None
patent: 9313798 (1993-07-01), None
patent: 9417828 (1994-08-01), None
patent: 9519790 (1995-07-01), None
patent: 9711718 (1997-04-01), None
patent: 9718838 (1997-05-01), None
patent: WO 99/61040 (1999-12-01), None
patent: WO 99/61040 (1999-12-01), None
patent: WO 00/20459 (2000-04-01), None
patent: WO 00/72881 (2000-12-01), None
patent: WO 01/73444 (2001-10-01), None
patent: WO 01/96365 (2001-12-01), None
Suzuki, K. et al., “Semaphorin 7A initiates T-cell-mediated inflammatory responses through a1β1 integrin”, Nature, 446:680-684, 2007.
Tsunoda, I. et al., “Modulation of Experimental Autoimmune Encephalomyelitis by VLA-2 Blockade”, Brain Pathol., 17:45-55, 2007.
Van der Vieren et al., A Novel Leukointegrin alphadbeta2, Binds Preferentially to ICAM-3 Immunity 3:683-690 (1995).
Wang et al., “Differential regulation of airway epithelial integrins by growth factors” Am. J. Respir.Cell Mol. Biol. 15:664-672 (1996).
Watts, G.M., et al., “Manifestations of Inflammatory Arthritis Are Critically Dependent on FLA-1 superscript 1”, J. Immunology, 174:3668-3675, 2005.
Wayner et al., “The function of multiple extracellular matrix receptors in mediating cell adhesion to extracellular matrix: preparation of monoclonal antibodies to the fibronectin receptor that specifically inhibit cell adhesion to fibronectin and react with platelet glycoproteins Ic-IIa” J. Cell Biol. 107:1881-1891 (1988).
Weinacker et al., “Role of the Integrin alphavbeta6 in Cell Attachment to Fibronectin” J. Biol.Chem. 269:6940-6948 (1993).
Woessner et al., “The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid” Arch. Biochem. Biophys. 93:440-447 (1961).
Yao et al., “Laminins promote the locomotion of skeletal myoblasts via the alpha 7 integrin receptor” J. Cell Science 109:3139-3150 (1996).
Yednock, T.A. et al., “Prevention of experimental autoimmune encephalomyelitis by antibodies against a4β1 integrin”, Nature, 356:63-66, 1992.
Bank, I. et al., “Expression and Functions of Very Late Antigen 1 in Inflammatory Joint Diseases”, J. Clin. Immunol. 11 (1):29-38, 1991.
Bennett et al., “Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody” Proc. Natl. Acad. Sci.USA 80:2417-2421 (1983).
Boerner et al., “Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro—Primed Human Splenocytes” J. Immunol. 147:86-95 (1991).
Border et al., “Transforming Growth Factor Beta in Tissue Fibrosis” New England J. Medicine 331:1286-1292 (1994).
Bossy et al., “Characterization of the Integrin Alpha8 subnit: A new intefrin beta1-associated subunit, which is prominently expressed on axons and on cells in contact with basal laminae in chick embryos” EMBO J. 10:2375-2385 (1991).
Brezinsky et al., “A Simple Method of Enriching Populations of Transfected CHO Cells for Cells of Higher Specific Productivity” J. Immunol. Methods 277:141-155 (2003).
Bridges et al., “Variable Region cDNA Sequences and Characterization of Murine Anti-Human Interferon y Receptor Monoclonal Antibodies that Inhibit Receptor Binding by Interferon y” Mol. Immunol. 32:1329-2989 (1995).
Camper et al., “Isolation, Cloning, and Sequence Analysis of the Integrin Subunit a10, a Bet1-associated Collagen Binding integrin Expressed on Chondrocytes*” J. Biol. Chem. 273:20383-20389 (1998).
Cerf-Bensussan et al., “The human intraepithelial lymphocyte marker HML-1 is an integrin consisting of a Beta7 subunit associated with a distinctive alpha chain” Eur. J. Immunol. 22:273-277 (1992).
Chapman, P.T. and Haskard, D.O., “Leukocyte adhesion molecules”, British Medical Bulletin, 51(2):296-311, 1995.
Clackson et al., “Making antibody fragments using phage display libraries” Proc. Natl. Acad. Sci.USA 352:624-628 (1991).
Colbert et al., “The effect of fluorescein labels on the affinity of antisera to small haptens” J. Imunol. Methods 140:227-233 (1991).
Cook et al., “Treatment with an Antibody to VLA-1 Integrin Reduces Glomerular and Tubulointerstitial Scarring in a Rat Model of Crescentic Glomerulonaphritis” Am. J. Pathol. 161:1265-1272 (2002).
International Search Report dated Nov. 13, 2000 from International Application No. PCT/US00/15004.
Davies et al., “Interactions of Protein Antigens with Antibodies” Proc. Natl. Acad. Sci. USA 93:7-12 (1996).
Diamond et al., “The I Domain is a Major Recognition Site on the Luekocyte Integrin Mac-1 (CD-11b/CD18) for Four distinct Adhesion Ligands” 120:1031-1043 (1993).
Elices, M.J. et al., “VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site”, Cell, 60:577-584, 1990.
Fiorucci et al., “Importance of Innate Immunity and Collagen Binding Integrin a1β1 in TNBS-Induced Colitis”, Immunity, 17, 769-780, 2002.
Fischmann et al., “Crystallographic Refinement of the Three-Dimensional Structure of the FabD1.3-Lysozyme Complex at 2.5-Å Resolution” J. Biol. Chem. 266:12915-12920 (1991).
Gardner et al., “Absence of integrin a1β1 in the mouse causes . . . wounded dermis”, J. Cell Science, 112, 263-272, 1999.
Gardner et al., “Deletion of Integrin a1 by Homologous . . . Cell Adhesion”, Developmental Biology, 175, 301-313, 1996.
Hemler et al. “Characterization of the Cell Surface Heterodimer VLA-4 and Related Peptides” J.Immunol. 262:11478-11485 (1987).
Hemler et al., “Glycoproteins of 210,000 and 130,000 M.W. on Activated T Cells: Cell Distribution and Antigenic Relation to Components on Resting Cells and T Cell Lines” J. Imunnol. 132:3011-3018 (1984).
Hessle et al., “Basement membrane diversity detected by monoclonal antibodies” Differentiation 26:49-54 (1984).
Hokibara et al., “Effects of monoclonal antibodies . . . CBA/J mice”, Clin. Exp. Immunol. 114, 236-244, 1998.
Holmes et al., “Conformational Correction Mechanisms Aiding Antigen Recognition by a Humanized Antibodyȁ
Garber Ellen A.
Karpusas Michael
Lyne Paul D.
Saldanha Jose William
Biogen Idec MA Inc.
Haddad Maher
Lando & Anastasi LLP
LandOfFree
Antibodies to VLA-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to VLA-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to VLA-1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4272694